Covalent binding of xenobiotics to specific proteins in the liver.

Chemicals that cause toxicity though a direct mechanism, such as acetaminophen, covalently bind to a select group of proteins prior to the development of toxicity, and these proteins may be important in the initiation of the events that lead to the hepatotoxicity. Disruption of the cell is measured by release of intracellular proteins such as alanine aminotransferase and occurs late in the time course following a hepatotoxic dose of a direct toxin. Prior to this disruption, there appears to be a large number of proteins covalently modified by a reactive metabolite. There are at least two possible mechanisms that may cause the toxicity. First, some critical protein is a target of the reactive metabolite. Disruption of the enzymatic function (or a critical pathway for a regulatory protein) may lead directly to cell death. With the direct hepatotoxin acetaminophen, there is a decrease in the activity of several of the early target proteins, but how this disruption of critical proteins leads to the toxicity is still unclear. The early targets appear to be proteins with accessible nucleophilic sulfhydryl groups, and usually the target has a high concentration of the protein within the cell. It is possible that the binding to some of these proteins represents a detoxification protecting more critical targets within the cell. A second mechanism for the direct toxicity is that more and more proteins become targets in the time course following administration of a direct toxin, and eventually the cells machinery is overwhelmed. The cell can then no longer function, or there is a disruption the redox balance within the cell due to the decreased function of numerous proteins. In contrast to the direct-acting toxins, the chemical-protein conjugates that initiate toxicity through an activation of the immune system appear to have a limited number of target proteins and are localized within one subcellular fraction. Halothane produces adducts almost exclusively in the microsomal fraction, and these adducts appear to be limited to selective proteins with high concentrations in this fraction. The substitution level is an important factor in the development of an immune response. Halothane hepatitis patients' antibodies primarily recognize proteins with a high substitution level. For halothane and diclofenac, the proteins are accessible to the immune system through exposure on the plasma membrane. Trichloroethylene binds primarily to a 50-kDa microsomal protein, and preliminary evidence has been presented which indicates that a trichloroethylene-protein conjugate is released into the blood following exposure, where contact with the immune system can occur. In order to elicit an immune response the immune system requires multiple exposure to the chemical-protein conjugates. With halothane hepatitis and with diclofenac hepatitis, as well as occupational and environmental exposure to trichloroethylene, there are multiple exposures leading to repeat presentation of the protein adducts to the immune system; this situation is not generally found with acetaminophen overdose patients. In summary, direct toxicants such as acetaminophen covalently bind to selected targets which may be critical to the development of hepatotoxicity, and they later form adducts with numerous proteins which may overwhelm the cell's capacity to maintain homeostasis, leading to loss of vital function and cell death (Fig.3). In contrast, indirect toxicants that elicit an immune-mediated toxicity such as halothane, and possibly diclofenac and trichloroethylene, appear to have a limited number of protein targets with a high substitution level, and the immune system is exposed repeatedly to the modified proteins.

[1]  L. Pohl,et al.  Mechanisms, chemical structures and drug metabolism , 1996, European journal of haematology. Supplementum.

[2]  E. Khairallah,et al.  Identification of a 54-kDa mitochondrial acetaminophen-binding protein as aldehyde dehydrogenase. , 1996, Toxicology and applied pharmacology.

[3]  N. Pumford,et al.  Acetaminophen-induced hepatotoxicity. Analysis of total covalent binding vs. specific binding to cysteine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[4]  L. Pohl,et al.  Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. , 1996, Chemical research in toxicology.

[5]  J. G. Kenna,et al.  Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. , 1996, Molecular pharmacology.

[6]  N. Pumford,et al.  Immunochemical detection of protein adducts in mice treated with trichloroethylene. , 1996, Chemical research in toxicology.

[7]  B. Martin,et al.  Glutamate dehydrogenase covalently binds to a reactive metabolite of acetaminophen. , 1996, Chemical research in toxicology.

[8]  B. Martin,et al.  Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. , 1995, Chemical research in toxicology.

[9]  B. Martin,et al.  cDNA cloning and baculovirus expression of the human liver endoplasmic reticulum P58: characterization as a protein disulfide isomerase isoform, but not as a protease or a carnitine acyltransferase. , 1995, Archives of biochemistry and biophysics.

[10]  Steven D. Cohen,et al.  Identification of the mouse liver 44-kDa acetaminophen-binding protein as a subunit of glutamine synthetase. , 1995, Toxicology and applied pharmacology.

[11]  L. Pohl,et al.  Processing of endoplasmic reticulum luminal antigens associated with halothane hepatitis in rat hepatocytes , 1995, Hepatology.

[12]  T G Myers,et al.  Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. , 1994, Chemical research in toxicology.

[13]  A. J. Gandolfi,et al.  Glutathione-S-transferase is a target for covalent modification by a halothane reactive intermediate in the guinea pig liver. , 1994, Toxicology.

[14]  L. Pohl An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. , 1993, Chemical research in toxicology.

[15]  L. Pohl,et al.  Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase , 1993, Hepatology.

[16]  B. Martin,et al.  Serum antibodies from halothane hepatitis patients react with the rat endoplasmic reticulum protein ERp72. , 1993, Chemical research in toxicology.

[17]  P. Harrison,et al.  Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis. , 1993, Carcinogenesis.

[18]  T. Myers,et al.  Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. , 1993, Chemical research in toxicology.

[19]  B. Martin,et al.  The calcium-binding protein calreticulin is covalently modified in rat liver by a reactive metabolite of the inhalation anesthetic halothane. , 1992, Chemical research in toxicology.

[20]  Steven D. Cohen,et al.  Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins. , 1992, Toxicology and applied pharmacology.

[21]  B. Martin,et al.  A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. , 1992, Biochemical and biophysical research communications.

[22]  K. Kilburn,et al.  Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. , 1992, Environmental research.

[23]  B. Martin,et al.  A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-alpha but has no activity. , 1991, Biochemical and biophysical research communications.

[24]  A. Mclean,et al.  Effect of paracetamol on mitochondrial membrane function in rat liver slices. , 1991, Biochemical pharmacology.

[25]  T J Bucci,et al.  Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. , 1991, The American journal of pathology.

[26]  D. Zakim,et al.  Diclofenac-associated hepatotoxicity. , 1990, JAMA.

[27]  R. Cook,et al.  DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. , 1990, Carcinogenesis.

[28]  N. Pumford,et al.  Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen protein adducts in subcellular liver fractions following a hepatotoxic dose of acetaminophen. , 1990, Biochemical pharmacology.

[29]  N. Pumford,et al.  Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice. , 1990, Toxicology and applied pharmacology.

[30]  Steven D. Cohen,et al.  Immunohistochemical localization of acetaminophen-bound liver proteins. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[31]  R. Birge,et al.  Immunochemical analysis of acetaminophen covalent binding to proteins. Partial characterization of the major acetaminophen-binding liver proteins. , 1988, Biochemical pharmacology.

[32]  J. Neuberger,et al.  Evidence for expression in human liver of halothane‐induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis , 1988, Hepatology.

[33]  P. Burcham,et al.  Effect of acetaminophen hepatotoxicity on hepatic mitochondrial and microsomal calcium contents in mice. , 1988, Toxicology letters.

[34]  H. Satoh,et al.  Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. , 1988, The Journal of pharmacology and experimental therapeutics.

[35]  Steven D. Cohen,et al.  Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. , 1988, Toxicology and applied pharmacology.

[36]  J. Neuberger,et al.  Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. , 1987, The Journal of pharmacology and experimental therapeutics.

[37]  T. Colby,et al.  Progressive systemic sclerosis associated with exposure to trichloroethylene. , 1987, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[38]  N. Pumford,et al.  A sensitive immunochemical assay for acetaminophen-protein adducts. , 1987, The Journal of pharmacology and experimental therapeutics.

[39]  Steven D. Cohen,et al.  Immunochemical detection of acetaminophen-bound liver proteins. , 1987, Biochemical pharmacology.

[40]  J. Mcnicholl,et al.  Fatal hepatitis associated with diclofenac. , 1986, Gut.

[41]  D. Schapira,et al.  Diclofenac-induced hepatotoxicity. , 1986, Postgraduate medical journal.

[42]  R. Schulick,et al.  Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. , 1985, Molecular pharmacology.

[43]  V. Ferrans,et al.  Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. , 1985, The Journal of pharmacology and experimental therapeutics.

[44]  J. Burton,et al.  A new syndrome with pigmentation, scleroderma, gynaecomastia, Raynaud's phenomenon and peripheral neuropath , 1978, The British journal of dermatology.

[45]  B B Brodie,et al.  Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. , 1973, The Journal of pharmacology and experimental therapeutics.

[46]  B B Brodie,et al.  Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. , 1973, The Journal of pharmacology and experimental therapeutics.

[47]  B. Martin,et al.  UDP-glucose:glycoprotein glucosyltransferase associates with endoplasmic reticulum chaperones and its activity is decreased in vivo by the inhalation anesthetic halothane. , 1997, Chemical research in toxicology.

[48]  B. Martin,et al.  Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[49]  N. Vermeulen,et al.  Metabolism and kinetics of trichloroethylene in relation to toxicity and carcinogenicity. Relevance of the mercapturic acid pathway. , 1995, Chemical research in toxicology.

[50]  A. J. Gandolfi,et al.  Formation and identification of protein adducts to cytosolic proteins in guinea pig liver slices exposed to halothane. , 1992, Toxicology.

[51]  I. Davidson,et al.  Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics. , 1991, Drug metabolism reviews.

[52]  V. Ferrans,et al.  Hapten carrier conjugates associated with halothane hepatitis. , 1991, Advances in experimental medicine and biology.

[53]  R. Chapman,et al.  Diclofenac associated hepatitis. , 1990, Journal of hepatology.

[54]  T. Green,et al.  Chloroethylenes: a mechanistic approach to human risk evaluation. , 1990, Annual review of pharmacology and toxicology.

[55]  P. Burcham,et al.  Mitochondrial dysfunction in paracetamol hepatotoxicity: in vitro studies in isolated mouse hepatocytes. , 1990, Toxicology letters.

[56]  N. Pumford,et al.  Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice. , 1989, The Journal of pharmacology and experimental therapeutics.

[57]  J. Blancato,et al.  Metabolism, toxicity, and carcinogenicity of trichloroethylene. , 1989, Critical reviews in toxicology.

[58]  B. Martin,et al.  Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  N. Pumford,et al.  Epitope characterization of acetaminophen bound to protein and nonprotein sulfhydryl groups by an enzyme-linked immunosorbent assay. , 1989, The Journal of pharmacology and experimental therapeutics.